Sage Journals: Discover world-class research

Abstract

Background:

Patient-reported and clinician-determined outcomes do not always correlate in clinical trials for psoriasis, even among those with clear skin.

Objective:

To compare clinical responses with patient-reported outcomes among patients with psoriasis enrolled in 2 phase 3, double-blind, controlled trials of guselkumab (VOYAGE 1 and VOYAGE 2).

Methods:

Overall, 1432 patients randomized to guselkumab, placebo, or adalimumab at baseline were included in the pooled patient population; measures were assessed at baseline and week 16. End points included proportions of patients achieving 100% improvement in their Psoriasis Area and Severity Index (PASI 100) score and summary scores = 0 on the Psoriasis Symptoms and Signs Diary (PSSD). Proportions of patients with PSSD symptom/sign summary scores = 0 and mean PSSD summary scores were summarized by PASI 100 status. Association between PASI and PSSD scores were evaluated using Pearson correlation coefficients.

Results:

Among week-16 PASI 100 responders, 46.8% and 34.1% reported PSSD symptom and sign summary scores = 0, respectively, and 30.9% and 49.0% reported minimal symptoms/signs (scores = 1 to <10), respectively; mean scores (scale 0-100) were 6.4 for symptoms and 5.8 for signs. Among PASI 100 nonresponders, only 11.1% (symptoms) and 7.5% (signs) reported PSSD summary scores = 0; mean scores were 25.7 and 26.7, respectively. Correlation coefficients between overall PASI response and PSSD scores were 0.63 (symptoms) and 0.68 (signs; both P < .0001).

Conclusion:

While PASI and PSSD scores were highly correlated and most PASI 100 responders reported no/minimal symptoms or signs at week 16, substantial discrepancies were found between complete clearance from the clinician’s view versus symptom/sign-free status from patients’ perspectives.

Keywords

complete clearance patient-reported outcomes PASI 100 psoriasis psoriasis symptoms and signs diary PSSD symptom-free

Get full access to this article

View all access options for this article.

References

Cline

Hill

Lewallen

Feldman

. Current status and future prospects for biologic treatments of psoriasis. Exp Rev Clin Immunol. 2016;12(12):1273–1287.

Ali

Cueva

Vyas

. A systematic review of the use of quality-of-life instruments in randomized controlled trials for psoriasis. Br J Dermatol. 2017;176(3):577–598.

Fredriksson

Pettersson

. Severe psoriasis oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244.

Finlay

Khan

. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216.

Mattei

Corey

Kimball

. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337.

Hesselvig

Egeberg

Dyrberg

Zachariae

Kofoed

Skov

. Correlation between dermatology life quality index and psoriasis area and severity index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98(3):335–339.

Reich

Nestle

Papp

. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br J Dermatol. 2006;154(6):1161–1168.

Elewski

Puig

Mordin

. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab. J Dermatol Treat. 2017;28(6):492–499.

Edson-Heredia

Banerjee

Zhu

. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016;30(5):852–909.

10.

Blauvelt

Papp

Griffiths

CEM

. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate-to-severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.

11.

Reich

Armstrong

Foley

. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate-to-severe psoriasis with randomized withdrawal and retreatment: results from the Phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.

12.

Blauvelt

Papp

Griffiths

CEM

. Correlation between PASI response and improvement in health-related quality of life over time: results from a phase III clinical trial VOYAGE 1. Poster presented at American Academy of Dermatology (P4921), March 3-7, 2017, Orlando, FL.

13.

Dawn

Yosipovitch

. Treating itch in psoriasis. Dermatol Nurs. 2006;18(3):227–233.

14.

Pithadia

Reynolds

Lee

. Psoriasis-associated cutaneous pain: etiology, assessment, impact, and management [published online ahead of print November 19, 2018]. J Dermatol Treat. 2018. doi:10.1080/09546634.2018.1528330

15.

Lebwohl

Swensen

Nyirady

Kim

Gwaltney

Strober

. The psoriasis symptom diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53(6):714–722.

16.

Mease

. The psoriasis symptom inventory: an effective patient-reported outcome measure of psoriasis severity. J Rheumatol. 2015;42(6):1034–1036.

17.

United States Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. 2009. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed November 3, 2018..

18.

Mathias

Feldman

Crosby

. Measurement properties of a patient reported outcome measure assessing psoriasis severity: the psoriasis symptoms and signs diary. J Dermatolog Treat. 2016;27(4):322–327.

19.

Feldman

Mathias

Schenkel

. Development of a patient-reported outcome questionnaire for use in adults with moderate-to-severe plaque psoriasis: the psoriasis symptoms and signs diary. J Dermatol & Dermatol Surg. 2016;20(1):19–26.

20.

Armstrong

Puig

Langley

. Validation of psychometric properties and development of response criteria for the Psoriasis Symptoms and Signs Diary (PSSD): results from a phase 3 clinical trial. J Dermatol Treat. 2019;30(1):27–34.

21.

Papp

Blauvelt

Kimball

. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial. J Eur Acad Dermatol Venereol. 2018;32(9):1515–1522.

22.

Kimball

Luger

Gottlieb

. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials. J Am Acad Dermatol. 2016;75(6):1156–1161.

23.

van Laarhoven

AIM

Kraaimaat

Wilder-Smith

van Riel

PLCM

van de Kerkhof

PCM

Evers

AWM

. Sensitivity to itch and pain in patients with psoriasis and rheumatoid arthritis. Exp Dermatol. 2013;22(8):530–534.

Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies

Abstract

Background:

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References